Sanofi, Regeneron Announce Sarilumab Phase 3 Study Meets Co-primary End Point

(RTTNews) - French drugmaker Sanofi (SNYNF, SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor.

The study met both its co-primary endpoints of improvements in signs and symptoms of rheumatoid arthritis (RA) and improvements in physical function who were inadequate responders to or intolerant of TNF-Alpha Inhibitors or TNF-IR, and secondary efficacy endpoints.

The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.

The companies to host Investor Conference Call on Sarilumab on Monday, Nov. 9 at 7:00 a.m. PT